A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 398 participants.
Also called NCT01105975
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 398 participants
- Sponsor
- Registry
-
NCT01105975
-
- Other papers using this trial's data
- Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib
- Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial
- Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Denmark, Germany, Netherlands, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01105975. Randomized; quadruple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2018-03-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
- Condition
- Dyslipidemia
- Intervention (Drug)
- LY2484595
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Simvastatin
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Placebo for LY2484595
- Intervention (Drug)
- Placebo for Statins
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01105975- Content hash
67ef3ffca17aabb17a4e87beaeb9f2fa45521ca5c00f4c11aa04f3b8f5398c03